Impact of SGLT inhibitors on multiple organ defects in diabetes.

07:00 EST 5th November 2019 | BioPortfolio

Summary of "Impact of SGLT inhibitors on multiple organ defects in diabetes."

Diabetes leads to multiple organ defects and cellular dysfunctions such as increased expression of sodium glucose like transporters (SGLTs). These transporters contribute to glucose homeostasis through glucose reabsorption in the proximal renal tubule. When inhibited, it results in reduced hyperglycemia, increased glucosuria and decreased HbA1c.


Journal Details

This article was published in the following journal.

Name: Current diabetes reviews
ISSN: 1875-6417


DeepDyve research library

PubMed Articles [22902 Associated PubMed Articles listed on BioPortfolio]

Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.

Type 2 diabetes (T2D) has a complex pathophysiology composed of multiple underlying defects that lead to impaired glucose homeostasis and the development of macrovascular and microvascular complicatio...

Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.

Many patients with type 1 diabetes (T1D) struggle to achieve glycaemic control and experience significant fluctuations in glucose concentrations, despite insulin treatment. Sodium-glucose co-transport...

Nephrolitiasis and Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A Meta-analysis Of Randomized Controlled Trials.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) decreased serum uric acid in type 2 diabetes. Hyperuricemia is associated with an increased risk of nephrolithiasis. The present meta-analysis, perfo...

Outcome studies on SGLT-2 inhibitors.

Inhibitors of sodium-glucose cotransporters type 2 (SGLT-2) are a class of oral antidiabetic drugs with a novel specific mode of action in the kidneys.

Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and major safety outcomes in adults with type 1 diabetes: a meta-analysis of randomized controlled trials.

Sodium-glucose cotransporter (SGLT) inhibitors added to insulin therapy have been proposed as a treatment strategy for type 1 diabetes (T1D). We thus conducted a meta-analysis of randomized controlled...

Clinical Trials [15454 Associated Clinical Trials listed on BioPortfolio]

Performance Under SGLT-2-Inhibitors in Humans

The PUSH Study is conceived to investigate the early effects of SGLT-2-Inhibitors on the physical performance of patients with Type-II-Diabetes mellitus compared to patients under other th...

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.

Empa PASS on Urinary Tract Malignancies

The aim of the study is to assess the risk of urinary tract malignancies in patients initiating empagliflozin (free or fixed dose combination) compared to patients initiating other sodium ...

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

This is a comparative effectiveness study comparing new users of SGLT-2 inhibitors with new users of other glucose lowering drugs with regard to hospitalization for heart failure and all c...

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study

Fatty liver disease is an increasingly recognized health problem in patients with type 2 diabetes mellitus (T2DM). Sodium glucose co-transporter type 2 (SGLT-2) inhibitors are a new class ...

Medical and Biotech [MESH] Definitions

A hereditary condition characterized by multiple symptoms including those of DIABETES INSIPIDUS; DIABETES MELLITUS; OPTIC ATROPHY; and DEAFNESS. This syndrome is also known as DIDMOAD (first letter of each word) and is usually associated with VASOPRESSIN deficiency. It is caused by mutations in gene WFS1 encoding wolframin, a 100-kDa transmembrane protein.

Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).

Congenital abnormalities that affect more than one organ or body structure.

A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.

Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.

Quick Search

DeepDyve research library

Relevant Topic

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Searches Linking to this Article